Replimune (REPL)

Company Profile

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.

Company profile

Ticker

REPL

Exchange

NASDAQ

Website

www.replimune.com

CEO

Robert Coffin

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Mar 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

SEC CIK

0001737953

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Replimune, Inc. • Replimune Limited • Replimune Securities Corporation • Replimune (Ireland) Limited ...

REPL stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$53.00

Low target

$34.00

High target

$70.00

Latest filings (excl ownership)

View all

8-K

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

4 Jan 23

8-K

Replimune Announces Proposed Public Offering

12 Dec 22

424B5

Prospectus supplement for primary offering

12 Dec 22

424B5

Prospectus supplement for primary offering

7 Dec 22

8-K

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

3 Nov 22

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

3 Nov 22

8-K

Entry into a Material Definitive Agreement

7 Oct 22

8-K

Submission of Matters to a Vote of Security Holders

4 Aug 22

Latest ownership filings

View all

Pamela Esposito

13 Dec 22

SC 13D/A

Atlas Venture Fund X, L.P.

Atlas Venture Fund X, L.P.

Financial summary

Financial statements Chart REPL financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 22	Mar 21	Mar 20	Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	90.57 mm	90.57 mm	90.57 mm	90.57 mm	90.57 mm	90.57 mm
Cash burn (monthly)	7.77 mm	5.92 mm	13.86 mm	12.01 mm	11.07 mm	8.96 mm
Cash used (since last report)	30.38 mm	23.14 mm	54.17 mm	46.95 mm	43.27 mm	35.04 mm
Cash remaining	60.19 mm	67.43 mm	36.39 mm	43.62 mm	47.30 mm	55.53 mm
Runway (months of cash)	7.7	11.4	2.6	3.6	4.3	6.2

Beta Read what these cash burn values mean

Financial data from Replimune earnings reports.

Institutional ownership, Q3 2022

REPL institutional ownership history Ownership history

95.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	103	104	-1.0%
Opened positions	11	7	+57.1%
Closed positions	12	11	+9.1%
Increased positions	46	34	+35.3%
Reduced positions	26	39	-33.3%

13F shares	Current	Prev Q	Change
Total value	734.48 mm	888.00 mm	-17.3%
Total shares	47.50 mm	48.66 mm	-2.4%
Total puts	0.00	0.00
Total calls	127.00 k	105.80 k	+20.0%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Omega Fund IV	5.01 mm	$0.00	0.0%
Omega Fund Management	4.29 mm	$74.06 mm	-8.2%
T. Rowe Price	4.17 mm	$72.04 mm	-29.1%
Baker Bros. Advisors	3.89 mm	$67.25 mm	+8.4%
Redmile	3.65 mm	$62.95 mm	0.0%
Atlas Venture Life Science Advisors	3.11 mm	$53.68 mm	-3.2%
BLK Blackrock	2.77 mm	$47.78 mm	+19.0%
Atlas Venture Fund X	2.16 mm	$40.62 mm	-14.3%
Vanguard	1.85 mm	$31.92 mm	+5.1%
Foresite Capital Fund III	1.23 mm	$18.64 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
T. Rowe Price	4.17 mm	-1.71 mm	-29.1%
STT State Street	0.00	-1.65 mm	EXIT
T. Rowe Price Investment Management	1.23 mm	+1.23 mm	NEW
BLK Blackrock	2.77 mm	+442.33 k	+19.0%
Great Point Partners	390.00 k	+390.00 k	NEW
Omega Fund Management	4.29 mm	-385.23 k	-8.2%
Atlas Venture Fund X	2.16 mm	-360.83 k	-14.3%
Baker Bros. Advisors	3.89 mm	+302.76 k	+8.4%
AMP Ameriprise Financial	216.67 k	+216.67 k	NEW
BMO Bank of Montreal	0.00	-215.93 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

REPL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Dec 22	Esposito Pamela	Common Stock	Sell	Dispose S	No	Yes	25.03	15,000	375.45 k	229,402
9 Dec 22	Esposito Pamela	Common Stock	Option exercise	Acquire M	No	No	1.01	15,000	15.15 k	244,402
9 Dec 22	Esposito Pamela	Employee Stock Option Common Stock	Option exercise	Dispose M	No	No	1.01	15,000	15.15 k	36,203
1 Dec 22	Konstantinos Xynos	Common Stock	Grant	Acquire A	No	No	0	17,500	0.00	70,798
1 Dec 22	Konstantinos Xynos	Employee Stock Option Common Stock	Grant	Acquire A	No	No	19.98	26,250	524.48 k	26,250
16 May 22	Robert Coffin	Common Stock	Sell	Dispose S	No	No	14.59	5,737	83.70 k	1,796,197
16 May 22	Philip Astley-Sparke	Common Stock	Sell	Dispose S	No	No	14.59	9,632	140.53 k	1,401,080